Medicare Enrolled
Dr. Sanjay Chabra, D.O.
Rheumatology · El Paso, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Chabra from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chabra?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Chabra
Dr. Sanjay Chabra is a rheumatology specialist in El Paso, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Chabra performed 257,179 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Chabra received a total of $3,318,791 from 51 pharmaceutical and/or device companies across 4845 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Chabra is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 3% volume in TX
$3,318,791 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗257,179
Medicare services
Top 3% in TX for rheumatology
Not available
Unique patients (not deduplicated)
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Tocilizumab injection (Actemra) | 172,720 | $5 | $14 |
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
52,400 | $4 | $13 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
25,352 | $10 | $33 |
| Denosumab injection (Prolia/Xgeva) | 2,880 | $18 | $54 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,201 | $75 | $270 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
792 | $98 | $345 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
358 | $54 | $189 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
356 | $117 | $364 |
| Ketorolac injection, per 15 mg An injection of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug, administered in doses measured per 15 mg. |
221 | $0 | $5 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
177 | $12 | $85 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
157 | $21 | $110 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
145 | $10 | $64 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
108 | $4 | $22 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
97 | $113 | $410 |
| New patient office visit, complex (60-74 min) | 75 | $144 | $521 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
55 | $37 | $184 |
| Methylprednisolone acetate injection, 80 mg An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication. |
34 | $8 | $40 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
21 | $48 | $270 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
16 | $52 | $175 |
| Methylprednisolone injection, up to 40 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg. |
14 | $3 | $10 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
10.2% high complexity
89.1% medium
0.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,318,791
Total received (2018-2024)
Avg $474,113/year across 7 years
Top 0% in TX for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
51
Companies
4,845
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$497,213
2023
$484,331
2022
$573,333
2021
$432,442
2020
$298,980
2019
$586,206
2018
$446,285
Payments by company (2024)
Amgen Inc.
$114,633
ABBVIE INC.
$108,508
AstraZeneca Pharmaceuticals LP
$88,827
GENZYME CORPORATION
$31,385
GlaxoSmithKline, LLC.
$29,342
UCB, Inc.
$28,670
Mallinckrodt Hospital Products Inc.
$20,934
Lilly USA, LLC
$18,984
Novartis Pharmaceuticals Corporation
$18,730
Aurinia Pharma U.S., Inc.
$13,731
ANI Pharmaceuticals, Inc.
$11,763
PFIZER INC.
$9,632
Janssen Biotech, Inc.
$809
SOBI, INC
$517
Actelion Pharmaceuticals US, Inc.
$338
Organon Llc
$134
E.R. Squibb & Sons, L.L.C.
$56
Cardinal Health Inc
$43
Alexion Pharmaceuticals, Inc.
$43
Boehringer Ingelheim Pharmaceuticals, Inc.
$39
Ultragenyx Pharmaceutical Inc.
$33
Fresenius Kabi USA, LLC
$30
Teva Pharmaceuticals USA, Inc.
$17
Genentech USA, Inc.
$14
Top 3 companies account for 62.7% of 2024 payments
All-time payments by company (2018-2024) ›
Horizon Therapeutics plc
$682,814
Amgen Inc.
$371,512
Lilly USA, LLC
$285,721
AbbVie Inc.
$221,052
ABBVIE INC.
$196,096
AstraZeneca Pharmaceuticals LP
$189,005
Horizon Pharma plc
$185,124
GlaxoSmithKline, LLC.
$180,125
Celgene Corporation
$159,736
UCB, Inc.
$147,373
GENZYME CORPORATION
$146,479
Aurinia Pharma U.S., Inc.
$121,206
AbbVie, Inc.
$116,856
Novartis Pharmaceuticals Corporation
$83,015
PFIZER INC.
$64,495
Mallinckrodt Hospital Products Inc.
$58,666
ANI Pharmaceuticals, Inc.
$30,612
Mallinckrodt Enterprises LLC
$23,960
Exeltis, USA Inc.
$13,366
Mallinckrodt LLC
$7,033
Janssen Biotech, Inc.
$6,998
Eli Lilly and Company
$6,400
Regeneron Healthcare Solutions, Inc.
$4,871
Genentech USA, Inc.
$4,713
Pfizer Inc.
$4,228
SOBI, INC
$1,854
NOVARTIS PHARMACEUTICALS CORPORATION
$1,725
SANOFI-AVENTIS U.S. LLC
$943
Actelion Pharmaceuticals US, Inc.
$388
Sobi, Inc
$314
Boehringer Ingelheim Pharmaceuticals, Inc.
$297
Genentech, Inc.
$280
Radius Health, Inc.
$224
Alexion Pharmaceuticals, Inc.
$175
Ultragenyx Pharmaceutical Inc.
$145
Flexion Therapeutics, Inc.
$136
Organon Llc
$134
E.R. Squibb & Sons, L.L.C.
$114
Takeda Pharmaceuticals U.S.A., Inc.
$95
DePuy Synthes Sales Inc.
$84
Janssen Pharmaceuticals, Inc
$76
Fresenius Kabi USA, LLC
$61
Gilead Sciences, Inc.
$61
MEDAC PHARMA, INC.
$45
Cardinal Health Inc
$43
Bioventus LLC
$39
Teva Pharmaceuticals USA, Inc.
$33
Biogen, Inc.
$28
Daiichi Sankyo Inc.
$17
Janssen Scientific Affairs, LLC
$14
Pacira Therapeutics, Inc.
$12
Top 3 companies account for 40.4% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · Amitiza · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · Crysvita · DUEXIS · Dojolvi · EVENITY · Enbrel · Exogen · FORTEO · GELSYN 3 · Gazyva · HADLIMA · HUMIRA · Humira · IDACIO · ILARIS · INFLECTRA · INJECTAFER · KEVZARA · KEVZARA SARILUMAB INJECTION · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · MONOVISC · NO PRODUCT DISCUSSED · NO_PRODUCT · NUCALA · OFEV · OLUMIANT · OPSUMIT · ORENCIA · ORTHOVISC · Otezla · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · REMICADE · RHEUMATOID ARTHRITIS DISEASE · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · STELARA · SYNAGIS · Strensiq · TALTZ · TAVNEOS · TEPEZZA · TEZSPIRE · TREMFYA · Tavneos · Truxima · Tymlos · UPLIZNA · UPTRAVI · Uloric · Ultomiris · VIMOVO · VRAYLAR · XELJANZ · Zilretta
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Rheumatologists in nearby ZIP areas
8
County median income
$58,859
Nearest hospital to ZIP centroid (approximate)
THE HOSPITALS OF PROVIDENCE - MEMORIAL CAMPUS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Chabra is a mixed practice specialist, with above-average Medicare volume (top 3% in TX), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Chabra experienced with tocilizumab injection (actemra)?
Based on Medicare claims data, Dr. Chabra performed 172,720 tocilizumab injection (actemra) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Chabra receive payments from pharmaceutical companies?
Yes. Dr. Chabra received a total of $3,318,791 from 51 companies across 4,845 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chabra's costs compare to other rheumatologists in El Paso?
Dr. Chabra's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chabra) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in El Paso
Browse rheumatologists in El Paso ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in TX
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in TX
Which TX rheumatologists receive the most from drug and device companies.
By company
Horizon Therapeutics plc Payments to Doctors
See all physicians who received payments from Horizon Therapeutics plc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology